Internal Medicine · Muncie, IN
NPI
1477526200
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3700 N Everbrook Ln
Muncie, IN, 47304
Phone (765) 288-8577
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
1,214 services
Medicare patients, 2024
192
Average age 77
Drug cost, 2024
$646K
5,286 prescriptions
Company payments, 2025
$639
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles B Dinwiddie Jr. was code 99213 (office e&m - established), 482 times for 175 patients. In total Charles B Dinwiddie Jr. billed 1,214 services in 23 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 482 | 175 | $58.91 | $28K |
| 99214 Office E&M - Established | Office | 237 | 131 | $87.42 | $21K |
| G0008 Administration of influenza virus vaccine | Office | 100 | 100 | $30.10 | $3,010 |
| 90656 Vaccine Product | Office | 100 | 100 | $21.90 | $2,190 |
| 93000 Electrocardiogram | Office | 33 | 32 | $8.58 | $283 |
| 99215 Office E&M - Established | Office | 29 | 26 | $137.41 | $3,985 |
| 99211 Office E&M - Established | Office | 27 | 11 | $16.44 | $444 |
| 81002 Clinical Chemistry | Office | 23 | 17 | $3.41 | $78.43 |
| 82274 Immunoassay | Office | 15 | 15 | $15.60 | $234 |
| 87811 Immunoassay | Office | 11 | 11 | $40.55 | $446 |
By year: 2022 $70K for 1,559 services; 2023 $54K for 1,262 services; 2024 $63K for 1,214 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 23 | 17 | $3.41 | $78.43 |
| 82274 Immunoassay | 15 | 15 | $15.60 | $234 |
| 87811 Immunoassay | 11 | 11 | $40.55 | $446 |
Medicare prescription drug claims, 2024
In 2024, the drug Charles B Dinwiddie Jr. prescribed most often to Medicare patients was Atorvastatin Calcium, with 531 prescriptions and refills. In total Charles B Dinwiddie Jr. wrote 5,286 Medicare prescriptions that cost $646K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 531 | 1,551 | 156 | $6,078 |
| Amlodipine Besylate Generic | 364 | 958 | 100 | $2,416 |
| Lisinopril Generic | 225 | 629 | 65 | $1,635 |
| Metformin Hcl Generic | 193 | 545 | 55 | $1,582 |
| Metoprolol Succinate Generic | 124 | 352 | 32 | $2,106 |
| Synthroid Levothyroxine Sodium | 109 | 247 | 29 | $8,967 |
| Meloxicam Generic | 108 | 252 | 41 | $581 |
| Tamsulosin Hcl Generic | 106 | 280 | 30 | $1,468 |
| Rosuvastatin Calcium Generic | 95 | 255 | 34 | $1,296 |
| Omeprazole Generic | 92 | 272 | 27 | $1,445 |
| Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide | 87 | 260 | 23 | $380 |
| Furosemide Generic | 83 | 228 | 30 | $370 |
| Pantoprazole Sodium Generic | 83 | 225 | 23 | $1,109 |
| Jardiance Empagliflozin | 78 | 196 | 20 | $111K |
| Allopurinol Generic | 77 | 216 | 19 | $887 |
Brand drugs: 648 claims; generic drugs: 4,610 claims; opioid claims: 86.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles B Dinwiddie Jr. $639 ($639 in general payments such as food, travel and fees) from 11 companies. The largest payer was Novo Nordisk Inc with $201.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 10 | $201 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $165 |
| Lilly USA, LLC LLY | 6 | $107 |
| GlaxoSmithKline, LLC. GSK | 2 | $35.36 |
| Abbvie Inc. ABBV | 2 | $32.98 |
| Pfizer Inc. PFE | 1 | $21.72 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $20.41 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $14.56 |
| Esperion Therapeutics, Inc. ESPR | 1 | $14.17 |
| Abbott Laboratories ABT | 1 | $13.78 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.